MDGL Madrigal Pharmaceuticals Inc.

81.68
-1.37  -2%
Previous Close 83.05
Open 82.95
Price To Book 2.86
Market Cap 1,260,253,299
Shares 15,429,154
Volume 260,204
Short Ratio
Av. Daily Volume 204,098
Stock charts supplied by TradingView

NewsSee all news

  1. Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))

    -- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled study in patients

  2. Madrigal Pharmaceuticals Announces Pricing of Secondary Offering

    WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and

  3. Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock

    CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and

  4. Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

    Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH: demonstrated that resmetirom treatment resulted in statistically significant reduction in

  5. Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

    CONSHOHOCKEN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights: "Madrigal continued to execute its clinical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data released February 8, 2018 - primary endpoint met.
MGL-3196
Heterozygous familial hypercholesterolemia (HeFH)
Phase 3 trial initiation announced March 28, 2019. Enrolment to be completed 2H 2020.
MGL-3196 (resmetirom)
Non-alcoholic steatohepatitis (NASH)
Phase 3 initiation of dosing announced December 18, 2019.
Resmetirom - MAESTRO-NAFLD-1
Non-Alcoholic Fatty Liver Disease

Latest News

  1. Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))

    -- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled study in patients

  2. Madrigal Pharmaceuticals Announces Pricing of Secondary Offering

    WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and

  3. Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock

    CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ("Madrigal" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and

  4. Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

    Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH: demonstrated that resmetirom treatment resulted in statistically significant reduction in

  5. Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights

    CONSHOHOCKEN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights: "Madrigal continued to execute its clinical